Trial Profile

Multicenter prospective registration and intervention studies for chemotherapy-induced peripheral neuropathy (MiroCIP Study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirogabalin (Primary)
Indications Chemotherapy-induced damage; Peripheral neuropathies
Focus Therapeutic Use
Acronyms MiroCIP

Most Recent Events

01 Dec 2023 New trial record
11 Nov 2023 Primary endpoint has been met, (Amount of change in the last 7-day pain (including tingling) NRS for 3 months after the administration start of Mirogabalin Besilate), as per Results published in the BMC Cancer
11 Nov 2023 Results published in the BMC Cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com